Drug Trial Radar · NCT07221513
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 15, 2025
Primary completion
Apr 16, 2026
Study completion Apr 16, 2026
Sponsor
- Lead sponsor
- Salubris Biotherapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.
Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Group 2 Pulmonary Hypertension
Interventions
JK07Drug
JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of TEAEs [Safety and tolerability]Time frame: Study entry through week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saint Francis Heart and Vascular Institute
Tulsa, Oklahoma
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.